Sitacity M 50/500
TM Tablets combine Sitagliptin, a DPP-4 inhibitor, with Metformin, a first-line antidiabetic agent, to provide comprehensive glycemic control in patients with type 2 diabetes mellitus. Sitagliptin enhances incretin hormone levels, improving insulin release and reducing glucagon secretion, while Metformin decreases hepatic glucose production and improves insulin sensitivity. This complementary mechanism helps achieve better overall glucose regulation.
Composition
- Sitagliptin 50 mg
- Metformin Hydrochloride 500 mg
Key Features & Benefits
- Dual Mechanism Action: Targets multiple pathways for improved glycemic control
- Low Hypoglycemia Risk: Particularly when compared to some other combination therapies
- Postprandial Control: Helps regulate blood glucose spikes after meals
- Weight Neutral Profile: Does not typically contribute to weight gain
- Improved Compliance: Combination therapy reduces pill burden
Recommended Usage
- To be taken as directed by a healthcare professional
- Preferably taken with meals to minimize gastrointestinal side effects
- Regular monitoring of blood glucose levels is advised
Safety Information
- Not recommended in patients with severe renal impairment
- Use cautiously in patients with a history of pancreatitis
- Monitor renal function periodically
- Consult a doctor if any unusual symptoms occur
Storage Instructions
- Store in a cool and dry place
- Protect from moisture and direct sunlight
- Keep out of reach of children
